Key clinical point: A combination of pembrolizumab and platinum chemotherapy is the most effective frontline treatment for patients with non–small cell lung cancer (NSCLC).
Major finding: Patients treated with immunotherapy had a significantly longer median overall survival than did patients treated with conventional therapy (hazard ratio, 0.76; P less than .001).
Study details: A retrospective study involving 16,228 patients with NSCLC.
Disclosures: The study was funded by the National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, and Guangzhou Science and Technology Program. The investigators disclosed no conflicts of interest.
Yu et al. JAMA Open. 2019 Jul 10. doi: 10.1001/jamanetworkopen.2019.6879.